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Abstract.	
	
	
The	article	presents	the	results	of	the	examination	of	128	patients	with	past	
ischemic	stroke	(on	the	4th	-5th	months	after	acute	cerebrovascular	disease).		
Enzyme	immunoassay	for	the	determination	of	NSE	concentration	in	blood	
serum	 of	 patients	 included	 into	 the	 study	 showed	 that	 the	 median	 of	 the	
distribution	of	enzyme	was	14.3	 (5.7;	57.8)	ng/ml	 (р<0.05)	 compared	 to	3.8	 (3.2;	
7.5)	 in	 patients	 of	 the	 control	 group.On	 the	 basis	 of	 the	 comparison	 of	 serum	
levels	 of	 NSE	 with	 the	 value	 of	 total	 NIHSS,	 MMSE	 and	 МоСА	 score	 more	
significant	 increase	 in	 this	parameter	was	detected	 in	patients	 with	 profound	
neurologic	 deficit	 and	 MCI.	 The	 analysis	 of	 serum	 NSE	 is	 an	 informative	
diagnostic	criterion	 for	 the	evaluation	of	neuronal	damage	 in	 the	brain	 leading	
to	 the	 inclusion	 of	detection	 of	NSE	 in	 clinical	practice	 to	 optimize	diagnostic	
procedures	in	patients	with	past	ischemic	stroke.	
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Problem	statement	and	analysis	of	the	recent	research	
	 The	prevalence	and	mortality	of	cerebral	stroke	and	its	complications	indicate	that	it	is	one	
of	the	most	important	medical	and	social	problems	in	Ukraine	and	worldwide	[1].	
	 Clinical	findings	and	the	results	of	conventional	methods	of	examination	may	not	always	
reflect	the	true	severity	of	the	condition,	the	degree	of	damage	to	the	central	nervous	system	(CNS)	
and	the	prognosis	of	the	development	of	the	disease.	It	justifies	the	need	to	search	for	new	markers	
of	 early	 diagnosis	 of	 brain	 ischemia	 aiming	 at	 pathogenetically	 justified	 intervention	 in	 the	
pathological	process,	restoration	of	normal	nervous	system	activity	and	reduction	in	the	incidence	
of	disabling	conditions.	
	 Over	the	past	decade,	functions	of	neuron-specific	proteins	(NSP)	as	markers	of	damage	to	
the	nervous	system	have	been	intensively	studied	in	neuroimmunology.	Neuron-specific	proteins,	
neuron-specific	 enolase	 (NSE)	 in	 particular,	 perform	 several	 functions	 simultaneously:	 they	 are	
involved	 in	 myelin	 formation	 and	 synaptic	 transmission	 of	 the	 nerve	 impulse;	 they	 catalyze	
specific	metabolism,	provide	molecular	mechanisms	of	learning	and	memory	[7,	10].	NSE	is	known	
to	be	a	glycolytic	isoenzyme	which	is	primarily	found	in	cells	of	neuroectodermal	origin	(in	cerebral	
neurons	and	peripheral	nervous	tissue)	[3,	4,	6,	13].	The	determination	of	NSE	is	used	in	diagnosing	
and	monitoring	the	efficacy	of	therapy.	It	is	also	a	prognostic	factor	for	a	range	of	diseases	such	as	
neuroendocrine	 tumors,	 oat	 cell	 cancer,	 neuroblastoma,	 traumatic	 brain	 injury,	 epilepsy.	 The	
determination	of	NSE	 is	helpful	after	surgeries	performed	on	patients	 	with	cardiac	pathology	as	
well	as	after	surgical	interventions	using	cardiopulmonary	bypass	[3,	6,	14].	The	promising	direction	
in	 modern	 angioneurology	 is	 the	 use	 of	 NSE	 as	 a	 tumor	 marker	 in	 patients	 with	 acute	
cerebrovascular	disease	 [3,	4,	6,	7].	 In	cerebral	 infarction,	hypoperfusion	of	brain	 tissues	 leads	 to	
neuronal	damage	as	a	result	of	which	NSE	and	other	substances	which	are	defined	as	markers	of	
neuronal	damage	release	[7].	Cell	markers	may	also	release	in	subarachnoidal	hemorrhage	due	to	
ruptured	 aneurysm	 [7,	 14].	 NSE	 is	 an	 important	 marker	 in	 evaluating	 acute	 complications	 as	 it	
correlates	with	the	degree	of	neuronal	damage	and,	therefore,	is	the	prognosis	of	the	diseases.	NSE	
increases	and	 reaches	 its	peak	values	on	 the	 first	day	of	 stroke.	The	primary	 increase	 in	 serum	
levels	of	NSE	is	followed	by	the	secondary	one	which	is	usually	less	significant	being	a	result	of	the	
secondary	damage	 to	brain	 tissues	due	 to	cerebral	edema	and	 increased	 intracranial	pressure	 [7,	
13].	 The	 secondary	 increase	 in	 serum	 levels	 of	 NSE	 may	 precede	 clinical	 signs	 indicating	 the	
progression	of	the	disease	[4,	7,	14].	
	 Thus,	the	study	of	the	concentration	of	NSE	in	blood	serum	of	patients	with	past	ischemic	
stroke	(IS)	is	of	great	relevance.		
	 The	objective	of	the	research	was	to	determine	the	concentration	of	marker	of	brain	damage	
-	neuron-specific	enolase	-	in	blood	serum	of	patients	with	past	IS.	
	 	
Materials	and	methods	
	 There	 were	 examined	 128	 patients	 with	 past	 IS	 (on	 the	 4th	 -5th	 months	 after	 acute	
cerebrovascular	disease)	at	 the	age	of	40-76	years	 (the	average	age	was	58.5	 ±	10.3)	The	diagnosis	
was	made	on	the	basis	of	anamnesis	and	complaints,	neurological	examination,	CT	or	brain	MRI.	
When	 performing	 CT	 or	 MRI	 signs	 of	 ischemic	 lesions	 of	 different	 localization	 and	 size	 were	
observed	 in	 all	 patients.	 The	 etiological	 factor	 for	 stroke	 was	 the	 coexistence	 of	 arterial	
hypertension	 and	 atherosclerotic	 lesion	 of	 the	 extracranial	 portion	 of	 the	 carotid	 arteries	 or	
diabetes	mellitus.		
	 There	 were	 88	 males	 and	 40	 females.	 93	 (68.7%)	 patients	 were	 diagnosed	 with	
atherothrombotic	stroke	and	25	(19.5%)	patients	were	diagnosed	with	cardioembolic	stroke.	Stroke	
Archive	of	Clinical	Medicine,	Vol.	22,	No.	1	(2016)	 ISSN	2414-9853	
	
	
Journal	homepage:	http://ojs.ifnmu.edu.ua/index.php/acm  
3	
was	 located	 in	the	 left	hemisphere	 in	77	 (60.1%)	patients	and	 in	51	 (39.8%)	patients	 it	was	 located	
in	 the	 right	hemisphere.	The	 control	group	 included	20	practically	healthy	persons	without	any	
signs	 of	 cerebrovascular	 pathology.	 The	 study	 was	 carried	 out	 at	 the	 department	 of	 vascular	
neurology	of	Ivano-Frankivsk	Regional	Clinical	Hospital	and	the	department	of	neurology	of	Ivano-
Frankivsk	City	Clinical	Hospital	No	1.	All	patients	gave	 informed	consent	 for	participation	 in	 the	
study.	
	 The	exlusion	criteria	were	reccurent	stroke,	sensory	aphasia,	severe	somatic	pathology.	
	 The	degree	of	neurologic	impairment	was	evaluated	using	the	National	Institute	of	Health	
Stroke	Scale.	The	following	methods	of	neuropsychological	assessment	were	used:	the	Mini-Mental	
State	Examination	or	Folstein	test	–	MMSE	(Folstein	et	al,	1975),	the	Clock-Drawing	Test	(Lezak	MD,	
1983)	and	the	Montreal	Cognitive	Assessment	–	MoCA	(Nasreddine	et	al,	2005).	
	 Neuron-specific	 enolase	 served	 as	 a	 marker	 of	 neuronal	 damage.	 Blood	 sampling	 was	
performed	in	the	morning	after	an	overnight	fast.	The	blood	was	then	centrifuged	at	2000	rpm.	The	
determination	of	NSE	was	performed	in	obtained	serum	samples	on	the	analyzer	by	the	method	of	
a	 solid-phase	 competitive	 enzyme	 immunoassay	using	human	NSE	 ELISA	 kits	produced	 by	DAI	
(USA)	according	to	the	manufacturer’s	instructions.	The	obtained	data	were	statistically	processed	
using	software	package	STATISTICA	6.0.	The	Mann-Whitney	U	test,	a	non-parametric	test	that	 is	
useful	 for	 determining	 two	 independent	 variables,	 was	 used	 to	 assess	 a	 statistically	 significant	
difference	between	groups.		
	 	
Results	and	discussion	
	 According	to	the	degree	of	neurologic	impairment	assigned	by	the	NIHSS	at	the	moment	of	
hospitalization	 all	 patients	 were	 divided	 as	 follows:	 45	 (35.1%)	 persons	 with	 mild	 neurological	
disorders	 (6.21±1.71	points);	 55	 (43%)	 persons	 with	 moderate	 neurologic	 impairment	 (10.58±1.04	
points);	28	(21.8%)	persons	with	severe	neurologic	impairment	(15.76±1.95	points).	
	 The	 results	of	 brain	MRI/CT	 revealed	 the	 signs	of	 internal	or	 concomitant	hydrocephaly,	
changes	 in	 the	 cerebral	 hemispheric	 white	 matter	 (focal	 changes,	 leukoaraiosis	 located	
periventricularly	and/or	 in	the	subcortical	regions	of	the	brain,	the	prefrontal	cortex)	generalized	
expansion	of	all	components	of	the	cerebrospinal	fluid	system	with	subsequent	brain	atrophy.	
	 When	 studying	 cognitive	 functions	 according	 to	 the	 MMSE	 scale	 the	 average	 score	 was	
24.2±0.37	points;	in	the	control	group	this	parameter	was	29.1±1.9	points	(p<0.05).	The	data	on	the	
incidence	of	cognitive	impairments	(CI)	of	different	severity	are	presented	in	Fig.1.	
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Normal cognitive function
Cognitive decline 
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Moderate post-stroke dementia
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Fig.1.	Incidence	of	cognitive	impairments	of	different	severity	according	to	the	MMSE	scale	
	 Enzyme	 immunoassay	 for	 the	 determination	 of	 NSE	 concentration	 in	 blood	 serum	 of	
patients	 included	 into	 the	study	showed	 that	 the	median	of	 the	distribution	of	enzyme	was	14.3	
(5.7;	57.8)	ng/ml	(р<0.05)	compared	to	3.8	(3.2;	7.5)	in	patients	of	the	control	group	(Table	1).	
	
Table	1	
Serum	level	of	NSE	in	blood	of	patients	with	past	ischemic	stroke	in	different	degrees	of	
neurological	disorders	
Neurologic	impairment	
according	to	the	NIHSS,	
points	
NSE,	ng/ml	
NSE,	ng/ml	
Control	group		
(n=	20)	
Patients	with	past	IS		
(n=	128)	
Mild	(n=45)	 10.25	(5.7;	19.2)*	
3.8	(3.2;	7.5)	 14.3	(5.7;	57.8)	Moderate	(n=55)	 13.9	(6.8;	35)*	
Severe	(n=28)	 16.9	(11.2;	57.8)*	
Notes:		
The	data	are	presented	as	a	median	(the	25th	and	75th	percentiles);	
*	Statistically	significant	difference	compared	to	the	control	group	(p<0.05)	
	 	
Therefore,	patients	with	past	IS	were	divided	into	two	groups:	Group	I	included	patients	with	serum	
NSE	levels	less	than	14	ng/ml	(n=68)	and	Group	II	included	patients	with	serum	NSE	levels	greater	
than	or	equal	 to	14	ng/ml	 (n=60).	When	comparing	cognitive	 functions	 lower	neuropsychological	
test	scores	were	observed	in	patients	with	serum	NSE	levels	greater	than	14	ng/ml	compared	to	the	
control	group	and	patients	with	less	serum	levels	of	NSE	(Table	2).	
	
Table	2	
Comparison	of	parameters	of	cognitive	functions	in	patients	with	past	IS	and	those	of	the	control	
group,	(М	±	m)	
Parameters	 Group	I	 Group	II	 Control	group	
MMSE	 26.36±0.2*	 24.15±0.19*^	 29.1±1.1	
МоСА	 24.04±0.17*	 21.6±0.21*^	 28.05±0.24	
Clock-Drawing	Test	 8.9±0.4	 8.1±0.5*	 9.2±0.8	
Notes:	
The	data	are	presented	as	a	median	(the	25th	and	75th	percentiles);	
*	Statistically	significant	difference	compared	to	the	control	group	(p<0.05);	
	^Statistically	significant	difference	compared	to	Group	I	(р<0.05)	
	 	
There	were	strong	correlations	between	serum	 level	of	NSE	and	 the	MMSE	score	 (R=-0.78;	
p<0.05)	and	between	NSE	and	 the	MoCA	score	 (R	=-0.71;	p<0.05).	The	obtained	data	may	 indicate	
the	possibility	of	using	the	determination	of	NSE	concentration	 in	blood	serum	for	the	validation	
of	diagnosis	of	an	increase	in	manifestations	of	post-stroke	CI	and	the	development	of	post-stroke	
dementia.	
	 On	the	basis	of	the	comparison	of	serum	 levels	of	NSE	with	the	value	of	total	NIHSS	score	
more	 significant	 increase	 in	 this	 parameter	 was	 detected	 in	 patients	 with	 profound	 neurologic	
deficit	 (Table	1).	Thus,	 in	group	of	patients	with	severe	neurologic	 impairment	the	median	of	the	
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indicator	of	NSE	was	16.9	(11.2;	57.8,	р<0.05)	that	exceeded	the	value	of	this	indicator	in	the	control	
group	by	25%	being	probably	caused	by	a	greater	extent	of	focal	changes	(Fig.2).	
	
Fig.2.	NSE	level	according	to	the	degree	of	neurologic	impairment	assigned	by	the	NIHSS	
Note:	
*	Statistically	significant	difference	compared	to	the	control	group	(p<0.05)	
	 	
There	 was	 a	 direct	 correlation	 between	 serum	 NSE	 and	 the	 severity	 of	 neurologic	
impairment	(R=0.71;	p<0.05)	indicating	the	direct	dependence	of	the	degree	of	post-ischemic	brain	
damage	and	neurological	disorders.	NSE	directly	reflects	the	depth	and	intensity	of	structural	and	
functional	 biomembrane	 abnormalities	 in	 the	 central	 nervous	 system,	 the	 severity	 of	
pathomorphological	changes	in	neurons	and	the	degree	of	blood-brain	barrier	permeability	[11,	12].	
	 The	analysis	of	 the	concentration	of	NSE	 in	blood	serum	 revealed	 its	 increase	 in	patients	
with	co-existent	somatic	diseases,	type	II	diabetes	mellitus	(type	II	DM)	and	ischemic	heart	disease	
(IHD)	 in	particular	 (p<0.05)	 (Table	2).	This	dependence	was	absent	 in	patients	with	chronic	 lower	
limb	venous	insufficiency	(CLLVI).	
	
Table	3	
Concentration	of	NSE	in	blood	serum	depending	on	the	presence	somatic	diseases	
Parameter	
Somatic	diseases	
Control	group	
IHD	 Type	II	DM	 CLLVI	
NSE	level,	ng/ml	
11.5	
(4.8;20.1)*	
16.4	
(4.9;	24.5)*	
11.2	
(4.3;	19.4)	
4.7	
(3.25;	7.55)	
Notes:	
The	data	are	presented	as	a	median	(the	25th	and	75th	percentiles);	
*	Statistically	significant	difference	compared	to	the	control	group	(p<0.05)	
	 	
Thus,	 the	 determination	 of	 serum	 NSE	 is	 an	 informative	 diagnostic	 criterion	 for	 the	
evaluation	of	neuronal	damage	in	the	brain.	
	 	
Conclusions	
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	 1.	The	 increase	 in	serum	 level	of	NSE	 in	patients	with	past	 ischemic	stroke	depending	on	
the	severity	of	cognitive	and	neurologic	impairment	being	of	diagnostic	value	was	established.	
	 2.	The	correlations	between	serum	level	of	NSE	and	the	severity	of	neurologic	impairment	
(R=0.71;	p<0.05)	and	between	the	MMSE	score	(R=-0.78;	p<0.05)	and	the	MoCA	score	(R	=-0.71;	p<0.05)	
were	detected.		
	 3.	The	deterioration	 in	 cognitive	 function	and	high	 serum	 levels	of	NSE	are	predictors	of	
unfavorable	prognosis.	
	 4.	The	 results	 indicate	 the	 informative	 value	 of	NSE	 level	 in	patients	with	past	 ischemic	
stroke	in	determining	the	degree	of	severity	leading	to	the	inclusion	of	detection	of	NSE	in	clinical	
practice	to	optimize	diagnostic	procedures	in	in	this	cohort	of	patients.	
	
Prospects	for	further	research	
	 Considering	 the	 prevalence	 and	 variety	 of	 clinical	 manifestations	 of	 this	 pathology	 the	
promising	direction	 is	 the	 study	of	 the	 influence	of	 changes	 in	 the	 concentration	of	markers	of	
post-ischemic	 damage	 and	 adhesion	 molecules	 on	 dynamics	 of	 neurologic	 state	 and	 cognitive	
impairments	 in	patients	with	past	 ischemic	stroke	undergoing	complex	neuroprotective	 therapy	
as	 well	 as	 the	 development	 of	 appropriate	 prognostic	 criteria	 to	 improve	 the	 effectiveness	 of	
therapeutic	measures	in	this	cohort	of	patients.	
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